Contrasting Soleno Therapeutics (SLNO) & Its Competitors
Soleno Therapeutics (NASDAQ: SLNO) is one of 82 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Soleno Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, earnings, profitability, dividends, risk and institutional ownership.
Insider and Institutional Ownership
65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 69.8% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Soleno Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Soleno Therapeutics Competitors||219||1276||2758||97||2.63|
Soleno Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 390.80%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.81%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Soleno Therapeutics is more favorable than its rivals.
Volatility & Risk
Soleno Therapeutics has a beta of 5.99, meaning that its share price is 499% more volatile than the S&P 500. Comparatively, Soleno Therapeutics’ rivals have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.
Earnings and Valuation
This table compares Soleno Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Soleno Therapeutics||$1.45 million||-$12.06 million||-1.02|
|Soleno Therapeutics Competitors||$975.11 million||$120.37 million||289.96|
Soleno Therapeutics’ rivals have higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Soleno Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Soleno Therapeutics Competitors||-431.69%||-47.45%||-16.12%|
Soleno Therapeutics rivals beat Soleno Therapeutics on 8 of the 13 factors compared.
About Soleno Therapeutics
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.